How Semax works

Semax is a short synthetic peptide. Researchers designed it as a longer-lasting cousin of a natural fragment of adrenocorticotropic hormone (ACTH) - specifically the ACTH(4–10) region - without the hormone’s steroid-raising effects. Decades of animal work point to several plausible pathways. None of them is settled as “the” mechanism. This page walks through the strongest published ideas in plain language, then flags what remains unknown.

Structure in one glance: MEHFPGP

Semax’s amino-acid sequence is:

Met–Glu–His–Phe–Pro–Gly–Pro (single-letter code: MEHFPGP, Semax’s seven-letter amino-acid code)

That shape matters for two historical reasons:

1. ACTH(4–10) core. The first four residues (MEHF) match the classic ACTH(4–7) “message” region that, in older peptide pharmacology, was linked to behavioral and cognitive effects more than to adrenal steroid release.
2. Pro–Gly–Pro (PGP) tail. Natural ACTH(4–10) breaks down quickly in blood. Russian teams in the late 1970s–1980s replaced the C-terminal tripeptide with Pro–Gly–Pro, which slowed enzymatic breakdown and extended measurable behavioral activity in animals to many hours rather than minutes.

Peer-reviewed summaries from the Institute of Molecular Genetics (IMG RAS) describe Semax as non-corticotropic: it was selected to keep neurotropic effects while avoiding ACTH’s endocrine (cortisol-raising) activity. That design story is well documented in Russian primary literature; sensational “secret ops lab” origin stories are not established in peer-reviewed sources (see origin cross-check below).

Brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB): the best-supported molecular story

Plain language: BDNF is one of the brain’s “grow and adapt” signals. Its main receptor is TrkB. When BDNF/TrkB signaling rises in places like the hippocampus, neurons can strengthen connections involved in learning and resilience to injury - at least in animal models.

Key experiment (often cited): Dolotov and colleagues (Brain Research, 2006) gave rats a single dose of Semax and measured hippocampal BDNF/TrkB:

• BDNF protein rose about 1.4-fold
• TrkB tyrosine phosphorylation (a marker of receptor activation) rose about 1.6-fold
• BDNF exon III mRNA rose about 3-fold; TrkB mRNA about 2-fold
• Animals also showed more conditioned avoidance responses (a learning measure)

Citation: Dolotov OV, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54–60. DOI: 10.1016/j.brainres.2006.07.108 · PMID: 16996037

Related work from overlapping groups reported:

• Specific binding of labeled Semax in rat basal forebrain membranes and a rise in BDNF protein there (Dolotov et al., Journal of Neurochemistry, 2006; PMID: 16635254).
• Rapid neurotrophin gene induction in glial cultures and region-specific changes after ischemia (e.g., Shadrina / Dmitrieva / Medvedeva lines of work in Cellular and Molecular Neurobiology, BMC Genomics, and related journals).

What this does not prove: Rising BDNF/TrkB in rats after a lab dose does not by itself explain every clinical claim, does not map cleanly to a single human brain region dose–response curve, and does not identify the upstream receptor that starts the cascade.

Dopaminergic and serotonergic modulation

Plain language: Dopamine and serotonin help shape motivation, attention, mood tone, and movement. Semax does not look like a classic stimulant that simply floods the brain with dopamine on its own.

Key experiment: Eremin et al. (Neurochemical Research, 2005) studied rodents and found:

• Striatal tissue 5-HIAA (a serotonin metabolite) rose (~25% at 2 h)
• Extracellular striatal 5-HIAA climbed gradually (up to ~180% over 1–4 h after intraperitoneal Semax in their protocol)
• Semax alone did not clearly raise dopamine or its metabolites
• Given before D-amphetamine, Semax amplified amphetamine-evoked dopamine release and locomotor activity

Citation: Eremin KO, et al. Semax, an ACTH(4–10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005;30(12):1493–1500. DOI: 10.1007/s11064-005-8826-8 · PMID: 16362768

Interpretation caution: “Activates serotonergic systems / modulates dopaminergic responses” is accurate for these animal data. It is not the same as saying Semax is an antidepressant, stimulant, or dopamine reuptake inhibitor in humans. Human monoamine pharmacology for Semax remains thinly published in English-language journals.

Melanocortin-receptor hypotheses

Because Semax is an ACTH/α-MSH family relative, researchers have long asked whether it acts at melanocortin receptors (MC1–MC5).

What the literature suggests (with caveats):

• Older pharmacological work on ACTH(4–10)-related peptides reported functional antagonism of α-MSH actions at MC4 and MC5 in some assays (often discussed via Adan / melanocortin-antagonist identification papers and secondary summaries). Semax is frequently described in reviews as a possible antagonist or partial agonist at MC4/MC5.
• Semax is repeatedly described as lacking MC2-linked corticotropic activity - consistent with its non-hormonal clinical profile - but modern, clean radioligand/cryo-EM binding packages for Semax at each MC subtype are not a settled textbook fact.
• Dolotov’s basal-forebrain binding work is important here: high-affinity sites for Semax were reported that appear distinct from classical melanocortin receptors. That undercuts any simple “Semax = MC4 ligand” story.

Bottom line for visitors: Melanocortin involvement is a plausible, historically grounded hypothesis, not a fully mapped receptor pharmacology.

Enkephalinase (peptidase) inhibition hypothesis

Plain language: Enkephalins are the body’s own short-lived opioid-like peptides. Enzymes in blood and tissue chop them up quickly. If a drug slows those enzymes, enkephalins (and some other regulatory peptides) may last longer.

Key experiment: Kost et al. (2001) reported that Semax and the related peptide Selank inhibit enkephalin-degrading enzymes from human serum, with Semax IC₅₀ around 10 µM (stronger in that assay than some classic peptidase inhibitors such as puromycin under their conditions). Peptide fragments mattered: certain shorter fragments retained activity; others did not.

Citation: Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganicheskaia Khimiia / Russian Journal of Bioorganic Chemistry. 2001;27(3):180–183. DOI: 10.1023/A:1011373002885 · PMID: 11443939

Flag: weakly linked to clinical effect so far: An IC₅₀ in the micromolar range in serum assays does not automatically mean that therapeutic exposures in the brain achieve meaningful enkephalinase blockade. Authors themselves framed this as one possible contributor among several. Clinical significance remains uncertain.

Broader gene-network and ischemia work

After experimental stroke in rats, Semax (and sometimes its PGP fragment) alters transcription of genes tied to:

• neurotrophins and receptors
• immune / inflammatory responses
• vascular / VEGF-related pathways

Examples include Dmitrieva et al. (Cellular and Molecular Neurobiology, 2010) and Medvedeva et al. (BMC Genomics, 2014). These studies support a pleiotropic (many-path) picture rather than a single “on/off switch.”

Origin cross-check

What we don’t know

Open questions

• Primary receptor identity. High-affinity binding sites exist in animal brain tissue, but the molecular identity of Semax’s main central nervous system (CNS) target is still not nailed down with modern receptor pharmacology.
• How BDNF induction starts. BDNF/TrkB changes are among the best-replicated molecular findings; the first step that triggers them is unclear.
• Melanocortin story completeness. Functional MC4/MC5 antagonism is discussed; direct, subtype-complete binding data for Semax itself remain thin.
• Enkephalinase relevance in vivo. Serum IC₅₀ data exist; brain exposure vs. enzyme inhibition at human-relevant levels is poorly quantified in open literature.
• Human monoamine imaging. Rodent serotonin/dopamine findings have little corresponding PET / functional MRI (fMRI)–neurochemistry package in Western journals.
• Causality vs. association in patients. Plasma BDNF rises have been reported alongside recovery measures in Russian stroke cohorts; that does not prove BDNF mediation in humans.
• Western independent replication of both mechanism and clinical claims is limited (see Evidence map).

Curiosity is warranted. Certainty is not.

Sources

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. https://doi.org/10.1016/j.brainres.2006.07.108 · PMID: 16996037
2. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4–10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493–1500. https://doi.org/10.1007/s11064-005-8826-8 · PMID: 16362768
3. Kost NV, Sokolov OY, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180–183. https://doi.org/10.1023/A:1011373002885 · PMID: 11443939
4. Ashmarin IP, Nezavibat'ko VN, Myasoedov NF, et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420–430. PMID: 9173745
5. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience & Medicine. 2013;4:223–252. https://doi.org/10.4236/nm.2013.44035
6. Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after focal brain ischemia in rats. Cell Mol Neurobiol. 2010;30(1):71–79. https://doi.org/10.1007/s10571-009-9432-0 · PMID: 19633950
7. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. https://doi.org/10.1186/1471-2164-15-228 · PMID: 24661604
8. Kaplan AY, Kochetova AG, Nezavibathko VN, Rjasina TV, Ashmarin IP. Synthetic ACTH analogue Semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19(2):115–123.
9. Adan RAH, et al. Identification of antagonists for melanocortin MC3, MC4 and MC5 receptors (ACTH(4–10) analogue pharmacology context). Eur J Pharmacol. 1994;269(3):331–337. (historical MC antagonist identification; Semax-related sequence discussed in secondary reviews)
10. Alzheimer’s Drug Discovery Foundation: Cognitive Vitality researcher brief on Semax (independent Western evidence summary; mechanism and clinical gaps). https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Semax-Cognitive-Vitality-For-Researchers.pdf

Claims marked uncertain or weakly sourced above should not be restated as established fact.